Category Archives: Business of Biotech

2015: A Promising Year for Biotech Jobs

BIO_Career_Fair

If you’re in the biotech sector and are looking for a new career, you’re in luck: according to a recent survey by BioSpace, 70% of respondents believe new jobs will be on the horizon this year. The majority of respondents say that small firms will lead the hiring rush. The poll was split over where most hiring would occur, with 39% believing it would go to research and development jobs, and 39% believing it would Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

The Perfect Close

72263479

With a fast and furious finish, yesterday, March 2nd, the Nasdaq Composite (IXIC) closed at 5,008.10, marking the third day in history with a close above 5,000. Since 95% of US publicly traded biotech companies are listed on the Nasdaq exchange, the team at BIO couldn’t help but join the excitement. Back in 2000, the Nasdaq index was flourishing with dot coms. At that point there was no Facebook or Netflix and Google wasn’t public. Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , ,

Choose Wisely My Friend- Survey Says, Identifying the Right R&D Partner is the Most Challenging Aspect of Outsourcing Market

b9e35848296c8b6718258607ece28d99

A recent survey conducted by BIO confirms the increasing reliance on R&D outsourcing as biotech and pharmaceutical companies indicate speed, flexibility, and access to specialized resources drive pipeline strategies/decisions.  Despite these biopharma companies having veteran teams with outsourcing experience, our survey results help quantify inefficiencies facing nearly every relevant organization. The survey polled a group of small biotech companies about their experience with CROs and other contract service providers.  Over 80% of the companies surveyed were actively outsourcing portions of their pre-clinical or clinical pipelines.  Nearly two-thirds of the companies surveyed dedicated more than 20% of their entire budget to these services in 2014.  In addition, every company surveyed plans on maintaining Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

Don’t Go At It Alone- BIO BizLink and the Evolving R&D Marketplace

b9e35848296c8b6718258607ece28d99

With companies in the biotechnology industry more frequently outsourcing R&D pipelines, selecting the right contract organization becomes more important. BIO, along with OnDeckBiotech, has recently launched a new online platform, BIO BizLink, that facilitates these relationships between biopharma companies and contract service providers. BIO BizLink serves as a peer-rated database for contract manufacturing organizations (CMOs) and contract research organizations (CROs) and their specific capabilities, while additionally providing secure project management tools to help companies work Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

BIO Investor Forum Closing Plenary: How Fragile is the Biotech Rally After Five Positive Years?

2

Last week’s 13th Annual BIO Investor Forum closed on Wednesday with a plenary session asking, “How fragile is the biotech rally after five positive years?” Moderated by Todd Foley, Managing Director, MPM Capital, the panel included: Rachel King, CEO, GlycoMimetics and Chair, BIO Ellen Lubman, VP Strategy and Innovation, Forest Laboratories Vijay Murthy, Director, Ventures and Early Stage Collaborations, AbbVie Michael A. Margolis, RPh, Managing Director, ROTH Capital Partners Doug Fambrough, PhD, CEO, Dicerna Pharmaceuticals Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , ,